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Adrenal suppression and Cushing’s syndrome secondary to 
ritonavir and budesonide
D Gray, P Roux, M Carrihill, M Klein
To the Editor: Ritonavir is a protease inhibitor used in 
combination therapy for advanced HIV infection. In South 
Africa lopinavir/ritonavir is first-line therapy for children 
under 3 years of age where there is a history of perinatal 
exposure to the non-nucleoside reverse transcriptase inhibitor 
(NNRTI) nevirapine.1 Ritonavir is a potent inhibitor of hepatic 
cytochrome P450-CYP3A4 iso-enzyme activity. 
Inhaled or intranasal corticosteroids are commonly used 
in children with recurrent lower airways obstruction, allergic 
rhinitis and chronic obstructive airways disease. Although 
systemic absorption of inhaled corticosteroids occurs, side-
effects are uncommon at low or medium doses. 
Inhaled corticosteroids are metabolised by hepatic 
CYP3A4. Fluticasone, a corticosteroid used in children, is 
known to interact with ritonavir, resulting in high levels of 
corticosteroids, suppression of the adrenocortical axis and 
Cushing’s syndrome.2 There have been no reports of other 
inhaled corticosteroids causing adrenal suppression and 
Cushing’s syndrome. Budesonide and beclomethasone are 
reported to be associated with a lower risk of systemic side-
effects than fluticasone,3 and a literature review suggested that 
they be used as an alternative to fluticasone given the risk of 
suppression of the adrenocortical axis.2 
We report 3 cases of children presenting with a suppressed 
adrenocortical axis and Cushing’s syndrome as a consequence 
of budesonide and ritonavir co-therapy. 
Case reports
Case 1. A 4-year-old girl with perinatally acquired HIV 
infection had shown a good response to antiretroviral therapy 
over 29 months (HIV viral load <50 copies/ml). She received 
inhaled budesonide for recurrent cough and bronchodilator-
responsive wheeze and was later prescribed intranasal 
budesonide for allergic rhinitis. Her maximum daily dose of 
budesonide was 1 200 µg and her daily dose of ritonavir was 
300 mg/m2. She received no other cytochrome P450 inhibitors. 
After 3 months of inhaled and intranasal steroid she had facial 
lipohypertrophy, truncal obesity and facial hirsutism. Her 
inhaled steroid dose was decreased to 200 µg. One week later 
her early-morning cortisol level was less than 1 mmol/l. All 
budesonide therapy was stopped. Three weeks later her early-
morning cortisol level was 222 mmol/l.
Case 2. A 4-year-old girl with perinatally acquired HIV1 
infection had responded well to lopinavir/ritonavir-containing 
antiretroviral therapy for 30 months (HIV viral load <50 
copies/ml). She was diagnosed with bronchiolitis obliterans 
following severe recurrent lower respiratory tract infections 
and was managed on 200 µg budesonide daily. Her total daily 
dose of ritonavir was 235 mg/m2. She developed facial and 
truncal obesity, facial hirsutism and a buffalo hump after 2 
years on treatment with inhaled steroids. Blood pressure and 
blood sugar were normal. Her early-morning cortisol level was 
8 mmol/l. The lopinavir/ritonavir was switched to efavirenz. 
Her early-morning cortisol level was 278 mmol/l when 
repeated 4 weeks after stopping ritonavir.
Case 3. A 7-year-old boy with perinatally acquired HIV1 
infection and post-infective chronic obstructive airways disease 
had had a good response to antiretroviral therapy for 59 
months (HIV viral load <50 copies/ml). He had symptoms of 
recurrent lower airway obstruction on a background of chronic 
obstructive airways disease following previous severe bacterial 
pneumonia and tuberculosis. On prescribed inhaled fluticasone 
50 µg and salmeterol he developed facial and truncal obesity, 
a buffalo hump and facial hirsuitism within 2 months. 
His early-morning cortisol level was less than 1 mmol/l. 
Fluticasone was replaced with budesonide at 100 µg twice 
daily. One month after replacing fluticasone with budesonide 
there was no improvement in the phenotypic features and 
he had a persistently suppressed adrenal cortical axis (early-
morning cortisol 5 mmol/l). It is interesting to note that even 
with the Cushing’s symptoms his recurrent respiratory signs 
and symptoms persisted. Two weeks after stopping inhaled 
steroid therapy a repeat early-morning cortisol level was 5 
mmol/l, and a further 4 weeks later it was 115 mmol/l. An 
adrenocorticocotrophic hormone (ACTH) stimulation test 
showed a moderate response. 
Discussion
Adrenal suppression with ritonavir and concomitant 
fluticasone has been described in children and adolescents,2,4 
and it has been suggested that other inhaled corticosteroids 
such as budesonide may be safer, given the comparatively 
prolonged clearance of fluticasone.
Our cases demonstrate that budesonide, which is also 
metabolised by iso-enzyme CYP3A4, can produce adrenal 
Paediatric HIV Service, Groote Schuur Hospital, Cape Town, and Department of 
Pulmonology, Red Cross War Memorial Children’s Memorial Hospital, Cape Town 
D Gray, MB ChB, DCH, FRACP (Paed)
Paediatric HIV Service, Groote Schuur Hospital, and School of Child and Adolescent 
Health, University of Cape Town
P Roux, MB ChB, MPhil (Bioethics), MD, DCH, FCP (Paed)
Paediatric HIV Service and Department of Paediatric and Adolescent Endocrinology, 
Groote Schuur Hospital 
M Carrihill, MB ChB, DCH, FCP (Paed), Cert Endo & Metab (SA) Paeds, 
MPhil (Paeds Endo)
School of Child and Adolescent Health, University of Cape Town, and Department of 
Pulmonology, Red Cross War Memorial Children’s Hospital 
M Klein, MB ChB, FCP (Paed) 
Corresponding author: D Gray (diane.gray@uct.ac.za)
297
SCIENTIFIC LETTERS
      May 2010, Vol. 100, No. 5  SAMJ
suppression when used with ritonavir/lopinavir. HIV-infected 
children have a high incidence of chronic lung disease, which 
includes chronic obstructive respiratory disease.5 Given 
the large number of children who are prescribed ritonavir-
containing antiretroviral regimens, many may be exposed to 
co-treatment with budesonide.
The daily dose of budesonide used in our cases varied 
from 200 µg to 1 200 µg. Adherence to medication was 
assessed by verbal report and medication demonstration by 
the caregiver. In case 2 the child was given medication by 
a trained nurse in a children’s home and medication was 
boarded for us to review. Dosing of inhaled budesonide in 
children with obstructive lung disease is based on clinical 
response to treatment. Recommended dosing ranges from 
a low dose of 100 - 200 µg/d to higher doses of >400 µg/d. 
With the exception of case 1 these children were on moderate 
doses of budesonide only and in case 3 initially a low dose 
of fluticasone (50 µg/d). The fact that the children may have 
been overdosed cannot be entirely excluded. However, it 
appears that adrenal axis suppression can occur at standard 
recommended doses of budesonide and fluticasone when used 
concomitantly with ritonavir. This relationship requires further 
investigation.
The older nucleoside reverse transcriptase inhibitors (NRTIs) 
such as zidovudine and stavudine remain first-line therapy 
in our and other resource-limited settings. These drugs 
are associated with lipodystrophy and truncal obesity. It is 
important to consider Cushing’s syndrome as a differential 
diagnosis and that the diagnosis of adrenal suppression is not 
missed.6 
The combination of ritonavir and inhaled corticosteroids 
should be avoided. If co-therapy is necessary, careful physical 
examination and monitoring of adrenal axis function are 
essential. 
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High prevalence of hookah smoking among secondary 
school students in a disadvantaged community in 
Johannesburg
A Combrink, N Irwin, G Laudin, K Naidoo, S Plagerson, A Mathee
To the Editor: Smoking of hookahs (also known as water-pipes) 
represents an emerging trend in tobacco use.1 Hookah smokers 
are at risk for the same diseases caused by cigarette smoking – 
cancer, respiratory and heart diseases, and pregnancy-related 
complications. Globally, the highest rates occur in the North 
African and East Mediterranean regions and among young 
people in the USA and European countries.2 There has been 
little research on hookah smoking in southern Africa.
Methods
The Health, Environment and Development study,3 conducted 
by the South African Medical Research Council in five 
deprived areas of Johannesburg, observed surprisingly 
high rates of smoking in a community near the centre of 
Johannesburg. Anecdotal reports and direct observations 
pointed to a high frequency of hookah smoking as a possible 
explanation. Subsequently, undergraduate medical students of 
the University of the Witwatersrand were invited to conduct a 
health education workshop on the effects of hookah smoking 
in the secondary school serving this community. To inform the 
workshop, a baseline survey was conducted among the student 
population. All Grade 10 students were invited to participate. 
Approval to conduct the study was obtained from the school 
principal, and verbal consent was obtained from the individual 
students, following an explanation that the study was 
voluntary and anonymous and that the results would be used 
for research purposes only. The ages of participants (N=202) 
in the four classes were from 14 - 20 years (mean 16.3 years). 
Three students elected not to participate.
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